AstraZeneca PLC (AZN.L)


LSE - LSE Delayed Price. Currency in GBp
5,011.00-69.00 (-1.36%)
At close: 12:08 PM EDT
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open5,024.00
Prev Close5,080.00
Bid4,965.00 x 6100
Ask5,180.00 x 13000
Day's Range4,926.95 - 5,079.18
52wk Range3,680.00 - 5,505.00
1y Target EstN/A
Market Cap63.38B
P/E Ratio (ttm)28.63
BetaN/A
Volume2,474,823
Avg Vol (3m)2,799,716
Dividend & YieldN/A (N/A)
Earnings DateN/A
  • Market Realist8 hours ago

    Changes in AstraZeneca’s Profitability in 2Q16

    AstraZeneca is reducing its selling, general, and administrative expenses for better profitability. Its R&D costs will be in line with 2015.

  • Market Realist10 hours ago

    AstraZeneca and Its Oncology Segment’s Growth in 2Q16

    AstraZeneca's (AZN) oncology segment is another key focus area. The segment’s contribution increased to more than 15% in 2Q16.

  • American City Business Journals11 hours ago

    MedImmune won't be impacted by AstraZeneca sale of antibiotic business to Pfizer

    Pharmaceutical giant AstraZeneca's agreement to sell much of its antibiotics business won't impact operations at MedImmune, its Gaithersburg-based research and development arm, officials confirmed Wednesday. MedImmune's infectious disease and vaccine portfolio for AstraZeneca (AZN) is focused exclusively on biologics, while AstraZeneca's deal with Pfizer Inc. — worth up to $1.6 billion — is specific to its small molecule antibiotics business .